Skip to main content

Table 6 Cox analysis of metastasis-free survival (MFS) in the molecular subtypes (ER+/HER; ER-/HER2-; HER2+) according to Desmedt and co-workers [[31]]

From: Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients

  p HR 95% CI
B. Multivariate analysis
ER+/HER2- (n=332)
Age (<50 vs. ≥50 years) 0.920 1.025 0.634-1.656
pT stage (≤2cm vs. >2cm) 0.004 2.143 1.271-3.613
Histological grade (Grade 1 and 2 vs. grade 3) 0.456 1.255 0.691-2.283
AURKA (continuous variable) 0.001 1.734 1.242-2.419
  p HR 95 % CI
ER-/HER2- (n=80)
Age (<50 vs. ≥50 years) 0.644 0.825 0.365-1.865
pT stage (≤2cm vs. >2cm) 0.466 1.459 0.528-4.028
Histological grade (Grade 1 and 2 vs. grade 3) 0.590 0.768 0.294-2.005
AURKA (continuous variable) 0.858 0.943 0.497-1.791
  p HR 95 % CI
HER2+ (n=53)
Age (<50 vs. ≥50 years) 0.018 5.072 1.327-19.383
pT stage (≤2cm vs. >2cm) 0.485 1.510 0.475-4.802
Histological grade (Grade 1 and 2 vs. grade 3) 0.001 15.527 3.223-74.793
AURKA (continuous variable) 0.001 0.146 0.045-0.466
  1. AURKA is associated with MFS in the estrogen receptor positive but not in the estrogen receptor negative subtypes. B. Multivariate Cox regression.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us